Amido-amine dendrimer compositions
OwnerPradeep K. Dhal, Stephen Randall Holmes-Farley +2inventors
InventorsPradeep K. Dhal, Stephen Randall Holmes-Farley, Chad C. Huval, Steven C. Polomoscanik
Life of this patent
Estimating the term…
Abstract
Amide compounds, amide polymers and compositions, including amide compounds and amide polymers, may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, the amide polymers may be amido-amine dendrimers that may be formed via a series of iterative reactions.
Claims15
1-72. (canceled)
A pharmaceutical composition comprising:
- a) an amido-amine polymer comprising an amido-amine dendrimer derived from:
- (i) a multi-amine;
- and
- (ii) a multifunctional compound comprising two or more amine-reactive groups;
- and
- b) a pharmaceutically acceptable excipient.
A pharmaceutical composition comprising:
- a) at least one amido-amine polymer comprising at least one amido-amine dendrimer or residue thereof, said amido-amine dendrimer represented by the following Formula III:
- wherein
- R3 independently represents a group represented by the following Formula IV:
- wherein
- p, q and r independently represent an integer from 0-2;
- R4 independently represents
- wherein
- m independently represents an integer from 1-20;
- R5 independently represents a hydrogen radical;
- a substituted or un-substituted
- alkyl radical;
- a substituted or un-substituted aryl radical;
- or R5 and a neighboring R5 together represent a link or links comprising a residue of a crosslinking agent, a substituted or un-substituted alicyclic radical, a substituted or un-substituted aromatic radical, or a substituted or un-substituted heterocyclic radical;
- or R5 represents a link with another compound or a residue thereof;
- b) a crosslinking agent or residue thereof;
- and
- c) a pharmaceutically acceptable excipient.
A pharmaceutical composition comprising:
- a) at least one polymer comprising at least one amido-amine dendrimer or residue thereof, said amido-amine dendrimer represented by the following Formula VIII:
- wherein
- R6 independently represents a group represented by the following Formula IX:
- wherein
- p, q and r independently represent an integer from 0-2;
- R4 independently represents:
- where m independently represents an integer from 1-20;
- R5 independently represents a hydrogen radical;
- a substituted or un-substituted alkyl radical;
- a substituted or un-substituted aryl radical;
- or R5 and a neighboring R5 together represent a link or links comprising a residue of a crosslinking agent, a substituted or un-substituted alicyclic radical, a substituted or un-substituted aromatic radical, or a substituted or un-substituted heterocyclic radical;
- or R5 represents a link with another compound or a residue thereof;
- RA independently represents an R5 group or a —R4—CO—R6 group;
- R7 independently represents an R5 group or independently represents a group according to the following Formula XIV:
- R8 independently represents an R5 group or independently represents a group according to the following Formula XV:
- R9 independently represents an R5 group or independently represents a group according to the following Formula XVI:
- b) a crosslinking agent or residue thereof;
- and
- c) a pharmaceutically acceptable excipient.
A method of treating hyperphosphatemia, hypocalcemia, hyperparathyroidism, depressed renal synthesis of calcitriol, tetany due to hypocalcemia, renal insufficiency, and ectopic calcification in soft tissues including calcifications in joints, lungs, kidney, conjuctiva, and myocardial tissues, chronic kidney disease, ESRD and dialysis patients comprising administering to a patient in need thereof a therapeutically effective amount of at least one polymer comprising at least one amido-amine dendrimer or residue thereof, said amido-amine dendrimer derived from compounds represented by the following Formulas II and XI:
- wherein R independently represents a branched or unbranched, substituted or un-substituted alkyl radical;
- R2 independently represents a hydrogen radical or a branched or unbranched, substituted or un-substituted alkyl radical;
- and
- b) a pharmaceutically acceptable excipient.
A method of treating hyperphosphatemia, hypocalcemia, hyperparathyroidism, depressed renal synthesis of calcitriol, tetany due to hypocalcemia, renal insufficiency, and ectopic calcification in soft tissues including calcifications in joints, lungs, kidney, conjuctiva, and myocardial tissues, chronic kidney disease, ESRD and dialysis patients comprising administering to a patient in need thereof a therapeutically effective amount of at least one polymer comprising at least one amido-amine dendrimer or residue thereof, said amido-amine dendrimer derived from compounds represented by the following Formulas II and XII:
- wherein R independently represents a branched or unbranched, substituted or un-substituted alkyl radical;
- R2 independently represents a hydrogen radical or a branched or unbranched, substituted or un-substituted alkyl radical;
- and
- b) a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.